Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Pacira BioSciences
PCRX
Pacira BioSciences
Aging Global Population And Opioid Shift Will Expand Surgical Markets
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 5 Analysts
Published
13 May 25
Updated
20 Aug 25
0
Set Fair Value
0
votes
Share
AnalystHighTarget
's Fair Value
US$36.00
28.2% undervalued
intrinsic discount
20 Aug
US$25.84
Loading
1Y
78.5%
7D
3.8%
Author's Valuation
US$36.0
28.2% undervalued
intrinsic discount
AnalystHighTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystHighTarget Fair Value
US$36.0
28.2% undervalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-127m
964m
2014
2017
2020
2023
2025
2026
2028
Revenue US$963.6m
Earnings US$141.1m
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
7.46%
Pharma revenue growth rate
0.58%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.78%
Calculation
US$141.07m
Earnings '28
x
12.74x
PE Ratio '28
=
US$1.80b
Market Cap '28
US$1.80b
Market Cap '28
/
41.41m
No. shares '28
=
US$43.39
Share Price '28
US$43.39
Share Price '28
Discounted to 2025 @ 6.78% p.a.
=
US$35.65
Fair Value '25